GlassScriptPhysician profile
Kerian Dodds
NPI 1902250723
$3,644.30
in general payments reported to CMS, 2019-2025
15 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $31.61 · 2023: $493 · 2024: $1,042 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.30 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,090.50 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $735.77 | 2023-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $412.54 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $276.45 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $234.40 | 2019-2023 | |
| Madrigal Pharmaceuticals | $216.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Exact Sciences Corporation | $128.92 | 2023-2025 | The Cologuard Plus Collection Kit |
| Genzyme Corporation | $118.63 | 2024 | |
| Boston Scientific Corporation | $91.72 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $72.65 | 2023-2025 | Ocaliva |
| Astrazeneca Pharmaceuticals LP | $65.17 | 2024-2025 | Imfinzi |
| Pfizer INC. | $61.07 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $58.03 | 2025 | Iqirvo |
| Celltrion USA INC. | $57.89 | 2024-2025 | Vegzelma, Zymfentra |
| Mirum Pharmaceuticals, INC. | $23.58 | 2025 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerian Dodds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.